Page 209 - 2020_11-Haematologica-web

Case Reports
872, Cordeliers Research Center, Paris; 15Department of Internal Medicine, National Referral Center for Immune Cytopenias, Henri Mondor Teaching Hospital, Assistance Publique-Hopitaux de Paris, Creteil and 16Medical Intensive Care Unit, Henri Mondor Teaching Hospital, Assistance Publique-Hopitaux de Paris, Creteil, France
Correspondence:
PABLO BARTOLUCCI - pablo.bartolucci@aphp.fer
Acknowledgments: the authors would like to thank Thierry Peyrard, CNRGS Institut National de la Transfusion Sanguine, Paris;
Claire Boulat, Etablissement français du sang, Le Kremlin-Bicetre; Paris; Badrdine El Masmouhi, Etablissement français du sang, Poitiers; Maud Deray, Etablissement français du sang, Montpellier, for antibody screening data; Damien Oudin Doglioni and Myriam Maumy for their advice regarding the statistical analysis.
doi:10.3324/haematol.2020.253856
References
1. Habibi A, Mekontso-Dessap A, Guillaud C, et al. Delayed hemolytic transfusion reaction in adult sickle-cell disease: presentations, out- comes, and treatments of 99 referral center episodes. Am J Hematol. 2016;91(10):989-994.
2. Mekontso Dessap A, Pirenne F, Razazi K, et al. A diagnostic nomo- gram for delayed hemolytic transfusion reaction in sickle cell disease. Am J Hematol. 2016;91(12):1181-1184.
3. de Montalembert M, Dumont M-D, Heilbronner C, et al. Delayed hemolytic transfusion reaction in children with sickle cell disease. Haematologica. 2011;96(6):801-807.
4. MerleNS,GrunenwaldA,RajaratnamH,etal.Intravascularhemol- ysis activates complement via cell-free heme and heme-loaded microvesicles. JCI Insight. 2018;3(12):96910.
5. Merle NS, Boudhabhay I, Leon J, Fremeaux-Bacchi V, Roumenina LT. Complement activation during intravascular hemolysis: Implication
for sickle cell disease and hemolytic transfusion reactions. Transfus
Clin Biol. 2019;26(2):116-124.
6. MerleNS,PauleR,LeonJ,etal.P-selectindrivescomplementattack
on endothelium during intravascular hemolysis in TLR-4/heme- dependent manner. Proc Natl Acad Sci USA. 2019;116(13):6280- 6285.
7. Pirenne F, Yazdanbakhsh K. How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reac- tions. Blood. 2018;131(25):2773-2781.
8. DumasG,HabibiA,OnimusT,etal.Eculizumabsalvagetherapyfor delayed hemolysis transfusion reaction in sickle cell disease patients. Blood. 2016;127(8):1062-1064.
9. Chonat S, Quarmyne M-O, Bennett CM, et al. Contribution of alter- native complement pathway to delayed hemolytic transfusion reac- tion in sickle cell disease. Haematologica. 2018;103(10):e483-e485.
10. Unnikrishnan A, Pelletier JPR, Bari S, et al. Anti-N and anti-Doa immunoglobulinG alloantibody-mediated delayed hemolytic trans- fusion reaction with hyperhemolysis in sickle cell disease treated with eculizumab and HBOC-201: case report and review of the lit- erature. Transfusion. 2019;59(6):1907-1910.
11. Vlachaki E, Gavriilaki E, Kafantari K, et al. Successful outcome of hyperhemolysis in sickle cell disease following multiple lines of treat- ment: the role of complement inhibition. Hemoglobin. 2018;42(5- 6):339-341.
12. Chou ST, Alsawas M, Fasano RM, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion sup- port. Blood Adv. 2020;4(2):327-355.
13. BatesD,MächlerM,BolkerB,WalkerS.Fittinglinearmixed-effects models using lme4. J Stat Softw. 2015;67(1):85262.
14. BoissierF,BagateF,SchmidtM,etal.Extracorporeallifesupportfor severe acute chest syndrome in adult sickle cell disease: a preliminary report. Crit Care Med. 2019;47(3):e26-e265.
15. Narbey D, Habibi A, Chadebech P, et al. Incidence and predictive score for delayed hemolytic transfusion reaction in adult patients with sickle cell disease. Am J Hematol. 2017;92(12):1340-1348.
haematologica | 2020; 105(11)
2697